MCID: CYT005
MIFTS: 49

Cytomegalovirus Retinitis

Categories: Eye diseases, Rare diseases

Aliases & Classifications for Cytomegalovirus Retinitis

MalaCards integrated aliases for Cytomegalovirus Retinitis:

Name: Cytomegalovirus Retinitis 12 53 44 15 17 72
Cmv Retinitis 12 55

Classifications:

MalaCards categories:
Global: Rare diseases
Anatomical: Eye diseases


External Ids:

Disease Ontology 12 DOID:0080160
MeSH 44 D017726
UMLS 72 C0206178

Summaries for Cytomegalovirus Retinitis

Disease Ontology : 12 A retinitis that has material basis in Cytomegalovirus.

MalaCards based summary : Cytomegalovirus Retinitis, also known as cmv retinitis, is related to granulocytopenia and posterior uveitis. An important gene associated with Cytomegalovirus Retinitis is CD9 (CD9 Molecule), and among its related pathways/superpathways are Innate Immune System and PEDF Induced Signaling. The drugs Ganciclovir and Valganciclovir have been mentioned in the context of this disorder. Affiliated tissues include eye, retina and t cells, and related phenotypes are cellular and hematopoietic system

Wikipedia : 75 Cytomegalovirus retinitis, also known as CMV retinitis, is an inflammation of the retina of the eye that... more...

Related Diseases for Cytomegalovirus Retinitis

Diseases related to Cytomegalovirus Retinitis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 377)
# Related Disease Score Top Affiliating Genes
1 granulocytopenia 30.4 TNF CSF2
2 posterior uveitis 30.2 TNF IFNG
3 uveitis 30.1 TNF IL10 IFNG HLA-B
4 pneumocystosis 30.0 TNF CD4
5 tuberculoid leprosy 29.9 IL10 IFNG
6 choroiditis 29.8 TNF IL10
7 panuveitis 29.8 TNF IL10 HLA-B
8 toxoplasmosis 29.7 TNF IL10 IFNG
9 herpes zoster 29.6 IL10 IFNG HLA-B
10 hematopoietic stem cell transplantation 29.5 TNF IL10 IFNG HLA-B
11 common variable immunodeficiency 29.4 TNF IL10 IFNG
12 hemophagocytic lymphohistiocytosis 29.3 TNF IL10 IFNG
13 crohn's disease 29.3 TNF IL10RA IL10
14 pulmonary tuberculosis 29.3 TNF IL10 IFNG
15 leprosy 3 29.3 TNF IL10 IFNG
16 connective tissue disease 29.3 TNF IL10 IFNG
17 proteasome-associated autoinflammatory syndrome 1 29.2 TNF IL10 IFNG
18 myasthenia gravis 29.2 TNF IL10 IFNG
19 colitis 29.2 TNF IL10RA IL10 IFNG
20 graft-versus-host disease 29.2 TNF IL10 IFNG HLA-B
21 aplastic anemia 29.0 TNF IFNG HLA-B CSF2
22 bacterial infectious disease 29.0 TNF IL10 IFNG CSF2
23 ulcerative colitis 28.9 TNF IL10RA IL10 IFNG
24 chronic graft versus host disease 28.9 TNF IL10 IFNG CD4
25 rheumatic disease 28.7 TNF IL10 IFNG HLA-B
26 skin disease 28.7 TNF IL10 IFNG HLA-B
27 acquired immunodeficiency syndrome 28.1 TNF IL10 IFNG HLA-B CSF2 CD4
28 human immunodeficiency virus type 1 27.8 TNF IL10 IFNG HLA-B CD9 CD4
29 human immunodeficiency virus infectious disease 27.4 TNF IL10 IFNG CD4 CCR2
30 neuroretinitis 11.2
31 retinitis 11.2
32 retinal detachment 10.8
33 immune deficiency disease 10.7
34 yemenite deaf-blind hypopigmentation syndrome 10.6
35 macular retinal edema 10.5
36 giant cell myocarditis 10.5 IL10RA HLA-B
37 pars planitis 10.5
38 neutropenia 10.5
39 endophthalmitis 10.4
40 large granular lymphocyte leukemia 10.4 IFNG CSF2
41 mucormycosis 10.4 IFNG CSF2
42 candida glabrata 10.4 IFNG CSF2
43 human t-cell leukemia virus type 2 10.4 IFNG CSF2
44 carotid artery thrombosis 10.4 IFNG CSF2
45 cytomegalovirus infection 10.4
46 anterior uveitis 10.4
47 cyclic neutropenia 10.4 IFNG CSF2
48 idiopathic bronchiectasis 10.4 IFNG HLA-B
49 drug reaction with eosinophilia and systemic symptoms 10.3 TNF HLA-B
50 histoplasmosis 10.3 IFNG HLA-B

Graphical network of the top 20 diseases related to Cytomegalovirus Retinitis:



Diseases related to Cytomegalovirus Retinitis

Symptoms & Phenotypes for Cytomegalovirus Retinitis

MGI Mouse Phenotypes related to Cytomegalovirus Retinitis:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.06 CCR2 CD4 CD9 CSF2 IFNG IL10
2 hematopoietic system MP:0005397 9.97 CCR2 CD4 CD9 CSF2 IFNG IL10
3 growth/size/body region MP:0005378 9.95 CCR2 CD4 CD9 CSF2 IFNG IL10
4 immune system MP:0005387 9.92 CCR2 CD4 CD9 CSF2 IFNG IL10
5 digestive/alimentary MP:0005381 9.91 CCR2 CD4 IFNG IL10 IL10RA TNF
6 neoplasm MP:0002006 9.65 CCR2 CSF2 IFNG IL10 TNF
7 no phenotypic analysis MP:0003012 9.55 CCR2 CD4 IFNG IL10 TNF
8 respiratory system MP:0005388 9.43 CCR2 CD9 CSF2 IFNG IL10 TNF
9 skeleton MP:0005390 9.1 CCR2 CD9 CSF2 IFNG IL10 TNF

Drugs & Therapeutics for Cytomegalovirus Retinitis

Drugs for Cytomegalovirus Retinitis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 107)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Ganciclovir Approved, Investigational Phase 4 82410-32-0 3454
2
Valganciclovir Approved, Investigational Phase 4 175865-60-8 64147
3
Cidofovir Approved Phase 4 113852-37-2 60613
4
Pancrelipase Approved, Investigational Phase 4 53608-75-6
5 Anti-Infective Agents Phase 4
6 Nucleic Acid Synthesis Inhibitors Phase 4
7 Antiviral Agents Phase 4
8 Ganciclovir triphosphate Phase 4
9 Gastrointestinal Agents Phase 4
10 pancreatin Phase 4
11
Sargramostim Approved, Investigational Phase 3 83869-56-1, 123774-72-1
12
Acyclovir Approved Phase 3 59277-89-3 2022
13 Antibodies Phase 2, Phase 3
14 Immunologic Factors Phase 3
15 Antibodies, Monoclonal Phase 2, Phase 3
16 Immunoglobulins Phase 2, Phase 3
17 Antineoplastic Agents, Immunological Phase 2, Phase 3
18
Nelfinavir Approved Phase 2 159989-64-7 64143
19 HIV Protease Inhibitors Phase 2
20
protease inhibitors Phase 2
21 Anti-HIV Agents Phase 2
22
Aldesleukin Approved Phase 1 85898-30-2, 110942-02-4
23 Analgesics Phase 1
24 Analgesics, Non-Narcotic Phase 1
25 Interleukin-2 Phase 1
26
Zidovudine Approved 30516-87-1 35370
27
Interferon beta-1b Approved 145155-23-3
28
Mycophenolic acid Approved 24280-93-1 446541
29
Ciprofloxacin Approved, Investigational 85721-33-1 2764
30
Prednisolone phosphate Approved, Vet_approved 302-25-0
31
Oxycodone Approved, Illicit, Investigational 76-42-6 5284603
32
Fosfomycin Approved 23155-02-4 446987
33
Alfentanil Approved, Illicit 71195-58-9 51263
34
Methylprednisolone Approved, Vet_approved 83-43-2 6741
35
Tazobactam Approved 89786-04-9 123630
36
Tranexamic Acid Approved 1197-18-8 5526
37
Molindone Approved 7416-34-4 23897
38
Cefepime Approved, Investigational 88040-23-7 5479537
39
Methylprednisolone hemisuccinate Approved 2921-57-5
40
Nifedipine Approved 21829-25-4 4485
41
Sevelamer Approved 52757-95-6
42
Aminocaproic acid Approved, Investigational 60-32-2 564
43
Amikacin Approved, Investigational, Vet_approved 37517-28-5 37768
44
Clozapine Approved 5786-21-0 2818
45
Spironolactone Approved 1952-01-7, 52-01-7 5833
46
Piperacillin Approved 66258-76-2 43672
47
Nafcillin Approved, Investigational 985-16-0, 147-52-4 8982
48
Tobramycin Approved, Investigational 32986-56-4 36294 5496
49
Haloperidol Approved 52-86-8 3559
50
Labetalol Approved 36894-69-6 3869

Interventional clinical trials:

(show top 50) (show all 73)
# Name Status NCT ID Phase Drugs
1 A Multicenter Study of Oral Versus Intravenous Hydration in AIDS Patients With CMV Retinitis Treated With Foscavir (Foscarnet Sodium) Completed NCT00002125 Phase 4 Foscarnet sodium
2 Ganciclovir-Cidofovir CMV Retinitis Trial (GCCRT) Completed NCT00000894 Phase 4 Cidofovir;Probenecid;Ganciclovir
3 Pharmacokinetics of Cidofovir During Continuous Venovenous Hemofiltration Completed NCT01866397 Phase 4
4 Use of Cidofovir Injection in the Treatment of Recurrent Respiratory Papillomatosis." Completed NCT00205374 Phase 4 Cidofovir;Placebo
5 Open, Randomised Study Comparing Preemptive Therapy With Intravenous Ganciclovir With and Without Additional Oral Ganciclovir for CMV Prophylaxis in Immunosuppressed Renal Transplant Patients Receiving Monitoring of CMV Viral Load Completed NCT00373165 Phase 4 Ganciclovir
6 Pharmacokinetics of Valganciclovir in Kidney and Kidney/Pancreas Transplant Recipients Completed NCT00034385 Phase 4 Valganciclovir
7 Open-Label Safety Study of Valganciclovir in Patients With CMV Retinitis and AIDS Who Have Complications Due to IV Treatment Unknown status NCT00017784 Phase 3 Valganciclovir
8 A Randomized, Controlled Study of Intravenous Ganciclovir Therapy for Peripheral Cytomegalovirus Retinitis in Patients With AIDS Completed NCT00000688 Phase 3 Ganciclovir
9 Foscarnet-Ganciclovir CMV Retinitis Trial Completed NCT00000136 Phase 3 Foscarnet;Ganciclovir
10 A Treatment Protocol for the Use of Intravenous Ganciclovir in AIDS Patients With Immediately Sight-Threatening CMV Retinitis Completed NCT00000698 Phase 3 Ganciclovir
11 Ganciclovir Implant Study for Cytomegalovirus Retinitis Completed NCT00000118 Phase 3
12 Cytomegalovirus Retinitis Retreatment Trial Completed NCT00000134 Phase 3 Ganciclovir;Foscarnet
13 Phase III Ganciclovir +/- rGM-CSF for AIDS-Related CMV Retinitis Completed NCT00002070 Phase 3 Sargramostim;Ganciclovir
14 Monoclonal Antibody CMV Retinitis Trial (MACRT) Completed NCT00000135 Phase 2, Phase 3 MSL-109
15 Studies of Ocular Complications of AIDS (SOCA)--Ganciclovir-Cidofovir CMV Retinitis Trial (GCCRT) Completed NCT00000143 Phase 3 Cidofovir intravenous
16 Studies of the Ocular Complications of AIDS (SOCA)--HPMPC Peripheral CMV Retinitis Trial (HPCRT) Completed NCT00000142 Phase 2, Phase 3 Cidofovir
17 A Comparison of Valganciclovir and Ganciclovir in the Treatment of Cytomegalovirus (CMV) of the Eyes Completed NCT00002377 Phase 3 Valganciclovir;Ganciclovir
18 A Phase III, Prospective, Randomized, Double-Blind Trial of Valganciclovir Pre-Emptive Therapy for Cytomegalovirus (CMV) Viremia as Detected by Plasma CMV DNA PCR Assay Completed NCT00006145 Phase 3 Valganciclovir
19 An Investigator Initiated Prospective Randomized, Controlled Pilot Study in Order to Evaluate the Place of Valganciclovir in Prevention of Cytomegalovirus Reactivation Following Allogeneic Stem Cell Transplantation Completed NCT00330018 Phase 3 Valganciclovir;Acyclovir
20 A Phase II, Randomized, Placebo-Controlled Study to Determine the Effects of Viracept on the Clinical Outcome of Cytomegalovirus (CMV) Retinitis in AIDS Patients Who Are Receiving Standard Induction and Maintenance Therapy for This Infection Completed NCT00002169 Phase 2 Nelfinavir mesylate
21 A Phase II/III Trial of Human Anti-CMV Monoclonal Antibody MSL 109 (MACRT) Completed NCT00000836 Phase 2 Sevirumab
22 An Open-Label Study of the Safety and Efficacy of Intravitreal ISIS 2922 in Acquired Immune Deficiency Syndrome (AIDS) Patients With Cytomegalovirus Retinitis (NOTE: Restricted to Patients Who Rollover From Another Controlled ISIS 2922 Trial) Completed NCT00002356 Phase 2 Fomivirsen sodium
23 A Randomized Comparison of Intravitreal ISIS 2922 Plus Ganciclovir Versus Ganciclovir as Treatment for Patients With Cytomegalovirus Retinitis ( CMVR ) Completed NCT00002156 Phase 2 Fomivirsen sodium;Ganciclovir
24 A Phase II/III Study of the Safety and Efficacy of 1-(S)-(3-Hydroxy-2-Phosphonylmethoxypropyl)Cytosine Dihydrate (Cidofovir; HPMPC) for the Treatment of Peripheral Cytomegalovirus Retinitis in Patients With AIDS Completed NCT00002437 Phase 2 Cidofovir;Probenecid
25 A Phase II, Double-Masked, Randomized, Placebo-Controlled Evaluation of Standard Therapy vs. Standard Therapy Combined With Human Monoclonal Anti-Cytomegalovirus Antibody (MSL 109) in the Therapy of AIDS Patients With Cytomegalovirus (CMV) Retinitis Completed NCT00001061 Phase 2 Sevirumab;Foscarnet sodium;Ganciclovir
26 CMV Retinitis Retreatment Trial Completed NCT00000766 Phase 2 Foscarnet sodium;Ganciclovir
27 A Phase II Dose-Ranging, Open-Labelled Trial of Foscarnet Salvage Therapy for AIDS Patients With Sight-Threatening CMV Retinitis Who Cannot Be Treated With Ganciclovir Due To Myelosuppression or Treatment Failure Completed NCT00000691 Phase 2 Foscarnet sodium
28 Phase II Randomized Study of Cidofovir for Peripheral Cytomegalovirus Retinitis Completed NCT00004794 Phase 2 cidofovir
29 A Randomized, Comparative, Placebo-Controlled Trial of the Safety and Efficacy of Oral Ganciclovir for Prophylaxis of Cytomegalovirus (CMV) Retinal and Gastrointestinal Mucosal Disease in HIV-Infected Individuals With Severe Immunosuppression Completed NCT00001034 Phase 2 Ganciclovir
30 A Phase II Randomized Controlled Trial of Immediate Versus Delayed Foscarnet Therapy in AIDS Patients With Non-Immediately Sight-Threatening CMV Retinitis Who Cannot Be Treated With Ganciclovir Due to Myelosuppression Withdrawn NCT00000697 Phase 2 Foscarnet sodium
31 A Phase I Study of the Safety of Proleukin (Aldesleukin) in Combination With Ganciclovir and Antiretroviral Therapy in HIV Seropositive Patients With Cytomegalovirus (CMV) Retinitis Completed NCT00002321 Phase 1 Aldesleukin
32 A Phase I/II Trial to Assess the Safety and Tolerance of Escalating Doses of a Human Anti-Cytomegalovirus Monoclonal Antibody (SDZ MSL-109) in Patients With the Acquired Immunodeficiency Syndrome and CMV Retinitis Completed NCT00002016 Phase 1 Sevirumab
33 A Phase I Study of a Fixed-Schedule Regimen of Alternating Oral and Intravenous Ganciclovir for Treatment of Cytomegalovirus Retinitis Completed NCT00001062 Phase 1 Ganciclovir
34 A Phase I/II Open-Labelled Trial of Intravitreal Ganciclovir Salvage Therapy for AIDS Patients With Active CMV Retinitis Who Are Intolerant of Systemic Therapy Completed NCT00000673 Phase 1 Ganciclovir
35 A Phase I Pharmacokinetic and Tolerance Study of 28-Day Regimens of Oral Ganciclovir Completed NCT00000668 Phase 1 Ganciclovir
36 A Phase I Open-Labeled Study of Long Term Combined or Alternating Foscarnet/Ganciclovir Maintenance Therapy for AIDS Patients With CMV Retinitis After Ganciclovir Induction Therapy Completed NCT00000970 Phase 1 Foscarnet sodium;Ganciclovir
37 Foscarnet Treatment of Serious CMV Retinitis Infection in Patients With Acquired Immunodeficiency Syndrome Completed NCT00000726 Phase 1 Foscarnet sodium
38 A Pharmacokinetic and Tolerance Study of Oral Ganciclovir in HIV-Infected Children With Asymptomatic Cytomegalovirus Infection and Low CD4 Cell Counts or Quiescent Cytomegalovirus Disease Completed NCT00000805 Phase 1 Ganciclovir
39 A Phase I/II Study of Cidofovir for HIV-Infected Children With Invasive CMV (Cytomegalovirus) Disease Withdrawn NCT00000881 Phase 1 Cidofovir;Probenecid
40 Foscarnet Treatment of Cytomegalovirus (CMV) Retinitis in AIDS Patients Not Eligible for Ganciclovir Therapy and Ganciclovir Treatment Failures Unknown status NCT00002301 Foscarnet sodium
41 Vistide (Cidofovir Intravenous) Treatment IND Protocol for Relapsing Cytomegalovirus Retinitis in Patients With AIDS Unknown status NCT00002384 Cidofovir
42 An Open Study of Foscarnet Treatment of CMV-Retinitis in AIDS Patients Completed NCT00002432 Foscarnet sodium
43 A Randomized Comparison of Two Dosage Schedules of Intravitreal ISIS 2922 for Patients With Advanced Cytomegalovirus Retinitis Completed NCT00002187 Fomivirsen sodium
44 An Open Label Study of the Safety and Tolerability of Valganciclovir, an Oral Prodrug of Ganciclovir, for the Treatment of Cytomegalovirus Retinitis in Subjects With AIDS Completed NCT00002222 Valganciclovir
45 An Open-Label Safety Study of Oral Ganciclovir Maintenance Treatment of CMV Retinitis in People With Limited Venous Access Completed NCT00002135 Ganciclovir
46 An Open Study of Foscarnet Treatment First Episode CMV-Retinitis in AIDS Patients Completed NCT00002039 Foscarnet sodium
47 A Study of the Safety and Tolerance of Long-Term Therapy With Intravenous Cytovene (Ganciclovir Sodium) for Cytomegalovirus Retinitis in Persons With AIDS Completed NCT00002034 Zidovudine;Ganciclovir
48 A Randomized Controlled Study of the Efficacy and Safety of Maintenance Treatment With Oral Ganciclovir for Newly Diagnosed Cytomegalovirus Retinitis in People With AIDS Completed NCT00002257 Ganciclovir
49 A Randomized Comparison of Immediate Versus Delayed Treatment With Intravitreal Injections of ISIS 2922 in Patients With Peripheral Cytomegalovirus (CMV) Retinitis Completed NCT00002355 Fomivirsen sodium
50 A Randomized Study Comparing the Safety and Efficacy of Three Doses of Oral Ganciclovir to Intravenous Ganciclovir for the Maintenance Treatment of Cytomegalovirus Retinitis in People With AIDS Completed NCT00002330 Ganciclovir

Search NIH Clinical Center for Cytomegalovirus Retinitis

Inferred drug relations via UMLS 72 / NDF-RT 51 :


Cidofovir
Cidofovir
fomivirsen
fomivirsen sodium
Foscarnet
Ganciclovir
Ganciclovir
Ganciclovir Sodium
valganciclovir
Valganciclovir
Valganciclovir hydrochloride

Cochrane evidence based reviews: cytomegalovirus retinitis

Genetic Tests for Cytomegalovirus Retinitis

Anatomical Context for Cytomegalovirus Retinitis

MalaCards organs/tissues related to Cytomegalovirus Retinitis:

41
Eye, Retina, T Cells, Kidney, Bone, Bone Marrow, Testes

Publications for Cytomegalovirus Retinitis

Articles related to Cytomegalovirus Retinitis:

(show top 50) (show all 2049)
# Title Authors PMID Year
1
Antiviral effects of foscarnet and ganciclovir therapy on human immunodeficiency virus p24 antigen in patients with AIDS and cytomegalovirus retinitis. Studies of Ocular Complications of AIDS Research Group in collaboration with AIDS Clinical Trials Group. 9 38
7658051 1995
2
Effect of foscarnet therapy on human immunodeficiency virus p24 antigen levels in AIDS patients with cytomegalovirus retinitis. 9 38
1323624 1992
3
A lymphoma patient with Cytomegalovirus retinitis and post-autologous hematopoietic cell transplantation immune reconstitution uveitis: A case report and review of the literature. 38
31033155 2019
4
Visual prognosis, clinical features, and predisposing factors in non-HIV patients with cytomegalovirus retinitis. 38
30030661 2019
5
Infectious uveitis in immunodeficient HIV-negative patients: A retrospective study. 38
31435074 2019
6
Autophagy protects against retinal cell death in mouse model of cytomegalovirus retinitis. 38
31291924 2019
7
CYTOMEGALOVIRUS RETINITIS AFTER AN INTRAVITREAL DEXAMETHASONE IMPLANT IN AN IMMUNOCOMPETENT PATIENT. 38
31339873 2019
8
Declining cytomegalovirus retinitis in ART- experienced women from North India. 38
31388246 2019
9
Safety and feasibility of virus-specific T cells derived from umbilical cord blood in cord blood transplant recipients. 38
31292125 2019
10
Routine Immediate Eye Examination at the Point of Care for Diagnosis of AIDS-Related Cytomegalovirus Retinitis Among Patients With a CD4 Count <100 in Myanmar. 38
31304189 2019
11
Utility of ultra-widefield retinal imaging in the follow-up and management of patients with Cytomegalovirus retinitis. 38
31268742 2019
12
[Diagnostic vitrectomy in intraocular inflammations: A retrospective series]. 38
31084938 2019
13
Presenting Features, Treatment and Clinical Outcomes of Cytomegalovirus Retinitis: Non-HIV Patients Vs HIV Patients. 38
31166809 2019
14
A comparative study on retinal thickness of the macular region among AIDS patients with normal ocular fundus, HIV-related microvascular retinopathy patients, and cytomegalovirus retinitis patients. 38
31261518 2019
15
Relationship Between Opacity of Cytomegalovirus Retinitis Lesion Borders and Severity of Immunodeficiency Among People With AIDS. 38
31042791 2019
16
Ultra-Widefield Fundus Autofluorescence in Cytomegalovirus Retinitis. 38
31136217 2019
17
Abnormal levels of aqueous humor trace elements in patients with cytomegalovirus retinitis. 38
31065104 2019
18
Aqueous cytomegalovirus DNA and interleukin-8 determination in management of cytomegalovirus retinitis. 38
30187638 2019
19
Cytomegalovirus retinitis in children and adolescents with acute leukemia following allogeneic hematopoietic stem cell transplantation. 38
30972869 2019
20
Bilateral cytomegalovirus retinitis comorbid with diabetic macular edema. 38
31198672 2019
21
Cytomegalovirus Retinitis during Maintenance Therapy in child with Acute Lymphoblastic Leukemia. 38
31086168 2019
22
[The ocular manifestations of human immunodeficiency virus and syphilis coinfection]. 38
30982288 2019
23
Polymerase chain reaction analysis of aqueous humor specimens in the diagnosis of cytomegalovirus retinitis in AIDS patients. 38
30968705 2019
24
Viral retinitis: diagnosis and management in the era of biologic immunosuppression: A review. 38
30859706 2019
25
[Clinical characteristics and T-lymphocyte subsets in 48 acquired immune deficiency syndrome patients with cytomegalovirus infections]. 38
30803177 2019
26
A cross-sectional study of cytomegalovirus retinitis in HIV-1 infected adults in Nigeria. 38
30837414 2019
27
Use of Letermovir as Salvage Therapy for Drug-Resistant Cytomegalovirus Retinitis. 38
30642941 2019
28
CD4+ cells as a potential biomarker for cytomegalovirus retinitis in children with acute lymphocytic leukemia. 38
30681505 2019
29
Active cytomegalovirus retinitis after the start of antiretroviral therapy. 38
30196272 2019
30
Concurrent cerebral toxoplasmosis and cytomegalovirus retinitis in a patient with human immunodeficiency virus. 38
30851795 2019
31
Uveitis causes according to immune status of patients. 38
30239127 2019
32
Cytomegalovirus Retinitis Associated with Lenalidomide Use for Multiple Myeloma in an Immunocompetent Patient. 38
30937202 2019
33
SOCS and Herpesviruses, With Emphasis on Cytomegalovirus Retinitis. 38
31031749 2019
34
Monitoring of cytomegalovirus infection in non-transplant pediatric acute lymphoblastic leukemia patients during chemotherapy. 38
30681620 2019
35
Macular oedema due to immune reconstitution uveitis occurring in an HIV-negative patient without cytomegalovirus retinitis. 38
30009623 2019
36
Cytomegalovirus retinitis, in a diabetic immunocompetent patient, after intravitreal ranibizumab injection. 38
29747535 2019
37
Host Genetics of Cytomegalovirus Pathogenesis. 38
31396258 2019
38
Visual acuity outcomes in cytomegalovirus retinitis: early versus late diagnosis. 38
30206157 2018
39
Ganciclovir-Induced Bullae Formation Secondary to Extravasation in a Patient Being Treated for Cytomegalovirus Retinitis. 38
30039977 2018
40
Diagnostic efficacy of real-time PCR for ocular cytomegalovirus infections. 38
30151602 2018
41
Initial intravitreal injection of high-dose ganciclovir for cytomegalovirus retinitis in HIV-negative patients. 38
30526535 2018
42
Spectrum of Newly Diagnosed Cytomegalovirus Retinitis in a Developing Country in the HAART Era. 38
30395753 2018
43
Opportunistic ocular infections in the setting of HIV. 38
30169465 2018
44
A review on recent drug delivery systems for posterior segment of eye. 38
30257375 2018
45
Case report: dual primary AIDS-defining cancers in an HIV-infected patient receiving antiretroviral therapy: Burkitt's lymphoma and Kaposi's sarcoma. 38
30409111 2018
46
"For your eyes only": ophthalmic complications following lung transplantation. 38
30622804 2018
47
Cytomegalovirus retinitis in HIV-negative patients - associated conditions, clinical presentation, diagnostic methods and treatment strategy. 38
29068151 2018
48
Synthesis, physicochemical properties and ocular pharmacokinetics of thermosensitive in situ hydrogels for ganciclovir in cytomegalovirus retinitis treatment. 38
29228826 2018
49
Ocular manifestations of cytomegalovirus in immunocompetent hosts. 38
30281031 2018
50
CYTOMEGALOVIRUS RETINITIS ASSOCIATED WITH OCCLUSIVE VASCULOPATHY IN AN ELDERLY, HUMAN IMMUNODEFICIENCY VIRUS-NEGATIVE MAN. 38
28937523 2018

Variations for Cytomegalovirus Retinitis

Expression for Cytomegalovirus Retinitis

Search GEO for disease gene expression data for Cytomegalovirus Retinitis.

Pathways for Cytomegalovirus Retinitis

Pathways related to Cytomegalovirus Retinitis according to GeneCards Suite gene sharing:

(show all 46)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.85 TNF IL10RA IL10 IFNG HLA-B CSF2
2
Show member pathways
13.51 TNF IL10RA IL10 IFNG CSF2 CD4
3
Show member pathways
13.26 TNF IL10RA IL10 CSF2 CD4 CCR2
4
Show member pathways
13.16 TNF IL10RA IL10 CSF2 CD4 CCR2
5
Show member pathways
13.03 TNF IL10RA IL10 IFNG HLA-B CSF2
6
Show member pathways
12.85 TNF IL10RA HLA-B CSF2 CD4
7
Show member pathways
12.67 TNF IL10RA IL10 IFNG HLA-B CD4
8
Show member pathways
12.51 TNF IL10 IFNG CD4
9
Show member pathways
12.51 TNF IL10RA IL10 IFNG CD4
10 12.47 TNF IL10 IFNG CCR2
11
Show member pathways
12.45 TNF IL10RA IL10 IFNG CD4
12
Show member pathways
12.42 TNF IFNG HLA-B CSF2
13
Show member pathways
12.37 TNF IL10 IFNG CSF2 CD4
14
Show member pathways
12.26 IL10RA IL10 IFNG CSF2 CCR2
15 12.21 TNF HLA-B CSF2
16
Show member pathways
12.2 TNF IFNG CSF2
17
Show member pathways
12.18 TNF IL10 IFNG HLA-B
18
Show member pathways
12.17 TNF IL10RA IL10 IFNG
19 12.14 TNF IL10RA IL10 IFNG
20
Show member pathways
11.99 IL10RA IL10 IFNG CD4
21
Show member pathways
11.96 TNF IFNG CSF2
22
Show member pathways
11.96 TNF IL10 IFNG CD4
23 11.93 TNF IFNG CCR2
24 11.81 TNF IFNG CSF2
25 11.8 TNF CSF2 CD9 CD4
26 11.79 TNF IL10 IFNG CSF2
27 11.78 IL10RA IL10 IFNG CCR2
28 11.72 TNF IL10 IFNG CSF2 CD4
29
Show member pathways
11.7 TNF IFNG CSF2
30
Show member pathways
11.61 TNF IFNG CSF2
31 11.61 TNF IL10 IFNG CD4
32 11.6 TNF CSF2 CCR2
33 11.52 TNF IL10 IFNG CSF2
34 11.48 TNF IL10 IFNG
35 11.46 TNF IFNG CCR2
36 11.44 IL10 IFNG CD4
37 11.42 TNF IL10 IFNG CSF2 CD4
38 11.31 TNF IL10 IFNG
39 11.3 TNF IL10RA IL10
40 11.26 IFNG HLA-B
41 11.2 TNF IFNG
42 11.13 IFNG CD4
43 11.1 IL10 IFNG
44 11.09 TNF IL10 CSF2
45 11.04 TNF IL10RA IL10 CSF2 CCR2
46 10.48 TNF IL10 IFNG CSF2 CD4

GO Terms for Cytomegalovirus Retinitis

Cellular components related to Cytomegalovirus Retinitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 integral component of plasma membrane GO:0005887 9.55 TNF HLA-B CD9 CD4 CCR2
2 cell surface GO:0009986 9.26 TNF HLA-B CD9 CD4
3 external side of plasma membrane GO:0009897 8.92 TNF CD9 CD4 CCR2

Biological processes related to Cytomegalovirus Retinitis according to GeneCards Suite gene sharing:

(show all 25)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of protein phosphorylation GO:0001934 9.75 TNF IFNG CD4
2 cellular response to lipopolysaccharide GO:0071222 9.73 TNF IL10 CSF2
3 cell surface receptor signaling pathway GO:0007166 9.62 IFNG CD4
4 negative regulation of extrinsic apoptotic signaling pathway in absence of ligand GO:2001240 9.62 TNF CSF2
5 negative regulation of mitotic cell cycle GO:0045930 9.61 TNF IL10
6 negative regulation of interleukin-6 production GO:0032715 9.61 TNF IL10
7 positive regulation of cytokine secretion GO:0050715 9.6 TNF IL10
8 positive regulation of protein complex assembly GO:0031334 9.59 TNF IFNG
9 positive regulation of T cell activation GO:0050870 9.58 CD4 CCR2
10 humoral immune response GO:0006959 9.58 TNF IFNG CCR2
11 positive regulation of osteoclast differentiation GO:0045672 9.57 TNF IFNG
12 positive regulation of membrane protein ectodomain proteolysis GO:0051044 9.55 TNF IFNG
13 positive regulation of heterotypic cell-cell adhesion GO:0034116 9.54 TNF IL10
14 negative regulation of growth of symbiont in host GO:0044130 9.52 TNF IL10
15 positive regulation of podosome assembly GO:0071803 9.51 TNF CSF2
16 cellular response to granulocyte macrophage colony-stimulating factor stimulus GO:0097011 9.49 CSF2 CD4
17 endothelial cell apoptotic process GO:0072577 9.48 TNF IL10
18 negative regulation of cytokine secretion involved in immune response GO:0002740 9.46 TNF IL10
19 positive regulation of interleukin-23 production GO:0032747 9.43 IFNG CSF2
20 cytokine-mediated signaling pathway GO:0019221 9.43 TNF IL10RA IL10 CSF2 CD4 CCR2
21 receptor biosynthetic process GO:0032800 9.37 TNF IL10
22 regulation of synapse organization GO:0050807 9.33 TNF IL10RA IL10
23 positive regulation of calcidiol 1-monooxygenase activity GO:0060559 9.32 TNF IFNG
24 positive regulation of vitamin D biosynthetic process GO:0060557 9.26 TNF IFNG
25 immune response GO:0006955 9.17 TNF IL10 IFNG HLA-B CSF2 CD4

Molecular functions related to Cytomegalovirus Retinitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytokine activity GO:0005125 8.92 TNF IL10 IFNG CSF2

Sources for Cytomegalovirus Retinitis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 TGDB
71 Tocris
72 UMLS
73 UMLS via Orphanet
Content
Loading form....